The Current Ratio as of November 2024 (TTM) for ImmunoCellular Therapeutics, Ltd. (IMUC) is 0

According to ImmunoCellular Therapeutics, Ltd.’s latest financial reports and current stock price. The company's current Current Ratio is 0. This represents a change of -100.00% compared to the average of 0.05 of the last 4 quarters.

ImmunoCellular Therapeutics, Ltd. (IMUC) Historical Current Ratio (quarterly & annually)

How has IMUC Current Ratio performed in the past?

The mean historical Current Ratio of ImmunoCellular Therapeutics, Ltd. over the last ten years is 8.75. The current 0 Current Ratio has changed -100.00% with respect to the historical average. Over the past ten years (40 quarters), IMUC's Current Ratio was at its highest in in the June 2015 quarter at 39.21. The Current Ratio was at its lowest in in the September 2020 quarter at 0.

ImmunoCellular Therapeutics, Ltd. (IMUC) Current Ratio by Quarter and Year

Discovering the peaks and valleys of ImmunoCellular Therapeutics, Ltd. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

ImmunoCellular Therapeutics, Ltd. (IMUC) Average Current Ratio

How has IMUC Current Ratio performed in the past?

The current Current Ratio of ImmunoCellular Therapeutics, Ltd. (IMUC) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

ImmunoCellular Therapeutics, Ltd. (IMUC) Current Ratio vs. Peers

How is IMUC’s Current Ratio compared to its peers?

ImmunoCellular Therapeutics, Ltd.’s Current Ratio is less than Northwest Biotherapeutics, Inc. (0.09), less than Catalyst Pharmaceuticals, Inc. (5.11), less than Oxford Cannabinoid Technologies Holdings Plc (4.03), less than Pharming Group N.V. (3.53), less than Kane Biotech Inc. (0.82), less than Health Sciences Group, Inc. (0), less than MedMira Inc. (0.22), less than Longboard Pharmaceuticals, Inc. (0), less than Lumos Pharma, Inc. (15.97), less than Cellectar Biosciences, Inc. (2.66), less than Bolt Biotherapeutics, Inc. (1.77), less than null (3.16),

Build a custom stock screener for ImmunoCellular Therapeutics, Ltd. (IMUC) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ImmunoCellular Therapeutics, Ltd. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

ImmunoCellular Therapeutics, Ltd. (IMUC) and other stocks custom spreadsheet templates

The easiest way to analyze a company like ImmunoCellular Therapeutics, Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.